HB+ is proud to partner with the National Minority Health Association to help bring about health equity and close the disparity gap in health and healthcare for underserved, marginalized, hard-to-reach, and minority communities.

The UCLA team played a pivotal role in a clinical trial that led to the FDA granting accelerated approval of the first antibody drug conjugate (ADC), mirvetuximab soravtansine, for the treatment of platinum-resistant ovarian cancer.

Read More